[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[@PGainz96934](/creator/twitter/PGainz96934)
"If this pullback continues heres my buy plan: $ALT: continue buying every day all day until double digits $AMD: continue loading under $XXX $BTC: slowly start accumulating below $100K $CAKE: continue weekly buys until $XX Simple. Disciplined. Long-term focused"  
[X Link](https://x.com/PGainz96934/status/1979295052552683609) [@PGainz96934](/creator/x/PGainz96934) 2025-10-17T21:14Z XXX followers, XXX engagements


"That sounds like a take that ignores fundamentals. $ALT Pemvidutide isnt a me-too GLP-1 like the rest. Its a balanced GLP-1/glucagon dual agonist showing XX % liver-fat reduction strong weight loss BIC muscle preservation no titration and best-in-class tolerability. Also with NITs showing fastest MASH and anti fibrotic activity of any incretin. Its dual-pathway profile gives it real shots in obesity MASH and AUD/ALD something most others cant claim. Do you have any data driven reasoning"  
[X Link](https://x.com/PGainz96934/status/1979871520953380886) [@PGainz96934](/creator/x/PGainz96934) 2025-10-19T11:25Z XXX followers, XXX engagements


"@Biotech2k1 Oh you think this is an obesity play No this is a MASH + AUD/ALD play that also has significant weight loss and best in class muscle preservation (which potentially makes it best in class obesity as well since losing skeletal muscle is not good)"  
[X Link](https://x.com/PGainz96934/status/1979874097988558959) [@PGainz96934](/creator/x/PGainz96934) 2025-10-19T11:35Z XXX followers, XX engagements


"So X things. 1) Its not an obesity okay which Ive said already multiple times. Its a mash play + AUD/ALD 2) If you insist on only looking at obesity are you not gonna layer in muscle preservation and % of lean body mass loss on these drugs. That significantly changes the landscape of the data. Id rather lose fat than lose skeletal muscle"  
[X Link](https://x.com/PGainz96934/status/1979879753210270082) [@PGainz96934](/creator/x/PGainz96934) 2025-10-19T11:58Z XXX followers, XX engagements


"@Biotech2k1 3) Not to mention XX vs XX weeks"  
[X Link](https://x.com/PGainz96934/status/1979880101350453589) [@PGainz96934](/creator/x/PGainz96934) 2025-10-19T11:59Z XXX followers, XX engagements


"@Biotech2k1 Haha okay I believe you have a fake biotech account and harvest for posts 🤣 no way youre a serious investor"  
[X Link](https://x.com/PGainz96934/status/1979881008460939636) [@PGainz96934](/creator/x/PGainz96934) 2025-10-19T12:03Z XXX followers, XX engagements


"Phase X trail what a trail You mean trial X. Speed to result Pemvidutide: 24-week data showing XX% resolution very rapid signal. Tirzepatide: Requires 52-week exposure to achieve XX% resolution at highest dose. Advantage: ALTs drug shows fast action. X. Resolution percentage Pemvidutides XXXX% is attractive vs placebo; tirzepatides highest (62%) is similar but over much longer duration. Comparable efficacy but ALTs at shorter term is seen as differentiated"  
[X Link](https://x.com/PGainz96934/status/1979881885195989058) [@PGainz96934](/creator/x/PGainz96934) 2025-10-19T12:06Z XXX followers, XX engagements


"@Biotech2k1 You continue to prove what I said earlier I think this is a fake biotech investing account 🤣 no way youre a real investor you sound like one of those FUD accounts on stocktwits"  
[X Link](https://x.com/PGainz96934/status/1979882673591255541) [@PGainz96934](/creator/x/PGainz96934) 2025-10-19T12:09Z XXX followers, XX engagements


"@bavariaron @GilaMonstrum Viking has serious tolerability issues severe ones as a matter of fact. Thats a major reason most drugs dont get past the FDA"  
[X Link](https://x.com/PGainz96934/status/1980064029394813052) [@PGainz96934](/creator/x/PGainz96934) 2025-10-20T00:10Z XXX followers, XXX engagements


"$NVO keeps rebranding incremental GLP-1 tweaks as next gen but the truth is the biology hasnt moved forward in years. Oral sema XX mg and CagriSema are just GLP-1 extensions chasing marginal gains. $ALT is already beyond that curve a balanced GLP-1 / glucagon dual agonist with: Biopsy-proven MASH resolution (59 % vs XX % PBO p 0.0001) in just XX weeks Massive liver-fat reduction (-5676 %) and cardiometabolic improvement No titration and best-in-class tolerability in MASH trials (01 % AE-related D/C) Early signals of muscle preservation (75 % fat-mass loss) something NO incretin can match"  
[X Link](https://x.com/PGainz96934/status/1980276120722219179) [@PGainz96934](/creator/x/PGainz96934) 2025-10-20T14:13Z XXX followers, XXX engagements


"@investseekers And you with $NVO"  
[X Link](https://x.com/PGainz96934/status/1980277913548116014) [@PGainz96934](/creator/x/PGainz96934) 2025-10-20T14:20Z XXX followers, XX engagements


"@TheMaverickWS Agreed same with $PLTR and $TSLA"  
[X Link](https://x.com/PGainz96934/status/1980312345730764930) [@PGainz96934](/creator/x/PGainz96934) 2025-10-20T16:37Z XXX followers, XXX engagements


"$ALT $SNY $AMGN Big game in MASH: the FDA accepted a Letter of Intent to qualify VCTE / FibroScan (liver stiffness) as a reasonably likely surrogate endpoint in non-cirrhotic MASH trials. Thats a regulatory milestone. Now layer on top Altimmunes 48-week IMPACT readout + EoP2 timing things could get explosive"  
[X Link](https://x.com/PGainz96934/status/1976720253162864872) [@PGainz96934](/creator/x/PGainz96934) 2025-10-10T18:43Z XXX followers, XXX engagements


"@texasrunnerDFW Unfortunately theyll be left to see higher prices in the future. As rates fall the top XX% will continue purchasing and so will be the RE funds. They got about another 3-6 months of declining prices before the prices start to rise again"  
[X Link](https://x.com/PGainz96934/status/1980719585646022830) [@PGainz96934](/creator/x/PGainz96934) 2025-10-21T19:35Z XXX followers, XX engagements


"@adirondackback @prosperousguy @HolySmokas I agree with that sentiment and numbers for MASH. Having said that it gets really interesting once we start adding in AUD/ALD and potentially oral delivery as well"  
[X Link](https://x.com/PGainz96934/status/1980767276719546407) [@PGainz96934](/creator/x/PGainz96934) 2025-10-21T22:44Z XXX followers, XX engagements


"That comeback story wont materialize without next-generation metabolic innovation and thats exactly where the future winners will separate themselves. Big Pharma like $PFE $NVO and $LLY have already extracted enormous value from first-gen GLP-1s. The next wave will be driven by multi-receptor incretin agonists with best-in-class tolerability muscle preservation and cross-indication potential (obesity + MASH + AUD/ALD). The only way any of the majors truly leap ahead again is by acquiring or partnering with a company that has that profile and Altimmunes Pemvidutide $ALT checks every box: Dual"  
[X Link](https://x.com/PGainz96934/status/1980746902346871256) [@PGainz96934](/creator/x/PGainz96934) 2025-10-21T21:23Z XXX followers, XXX engagements


"Exactly it was a smart and strategic move by $ALT to add AUD/ALD to the mix. It broadens their metabolic footprint beyond MASH and obesity and few realize how synergistic these indications actually are from a mechanistic standpoint. GLP-1/glucagon dual agonism isnt just about appetite it directly modulates reward pathways liver fat oxidation and metabolic inflammation. Thats why Pemvi is uniquely positioned to target both alcohol-driven liver disease and alcohol-use behavior something standard GLP-1s only scratch the surface on. Youre right that AUD trials are tricky (two reg trials longer"  
[X Link](https://x.com/PGainz96934/status/1980831521880637667) [@PGainz96934](/creator/x/PGainz96934) 2025-10-22T03:00Z XXX followers, XX engagements


"🚨 Major milestone for $ALT and Pemvidutide. Altimmunes Phase X IMPACT MASH study data have been selected for late-breaking oral and poster presentations at AASLD 2025 (The Liver Meeting) the premier global stage for hepatology innovation. Late-breaking means the data were considered both new and significant enough to warrant special inclusion after the normal submission deadline. This is a rare distinction that underscores the scientific and clinical importance of these results. With Pemvidutide already demonstrating industry-leading results in MASH obesity and fibrosis markers this"  
[X Link](https://x.com/PGainz96934/status/1980281812015292454) [@PGainz96934](/creator/x/PGainz96934) 2025-10-20T14:35Z XXX followers, 1406 engagements


"Lets slow down the BIC talk $VKTX own data doesnt back that up unless you have data that nobody else is privy to $ALT pemvidutide on the other hand has already shown XXXX% mean weight loss at XX weeks XX% fat loss / XX% lean and near-zero discontinuations all without titration. Add to that XX% MASH resolution (p 0.0001) and XX% liver-fat reduction and youve got clinical breadth $VKTX simply doesnt have. Running multiple Phase 3s best-in-class. Delivering elite efficacy muscle preservation and tolerability across obesity + MASH does and thats exactly what $ALT is doing"  
[X Link](https://x.com/PGainz96934/status/1980716464228204622) [@PGainz96934](/creator/x/PGainz96934) 2025-10-21T19:22Z XXX followers, XXX engagements


"Heres the simple compare + upside math: Market caps (today): $ALT $0.35B $VKTX $3.7B $MDGL $9.7B i.e. Viking is XX Altimmune; Madrigal is XX. Analyst consensus on $ALT: Recent averages cluster $17$20 12-mo PT (TipRanks avg $19.75; MarketBeat avg $17.40). HC Wainwright latest $XX reiterated. Even the lower end implies multi-bagger from here. Realistic upside framing: To consensus PT ($18$20): XX from a $X handle. To $VKTXs cap: would imply XX if pemvidutide lands a partnership/clear path in MASH/obesity (this is my BASE case). To $MDGLs cap: blue-sky 2530 if ALT becomes the next-gen metabolic"  
[X Link](https://x.com/PGainz96934/status/1980756032168292721) [@PGainz96934](/creator/x/PGainz96934) 2025-10-21T22:00Z XXX followers, XXX engagements


"Totally fair take but Im still holding $CAKE mainly because of the growth runway for North Italia and Flower Child. Both brands are scaling fast. Management plans to open XX locations each in 2025 and sees potential for 200+ units long term. North Italias upscale-casual model and Flower Childs health-driven fast-casual niche give CAKE exposure to segments that are still expanding even if traditional dining is slower. So while the core Cheesecake brand is mature these two concepts will drive the next leg of growth over the next XX years. Thats why Im still in. Im expecting 100-200% gains"  
[X Link](https://x.com/PGainz96934/status/1980851688866037773) [@PGainz96934](/creator/x/PGainz96934) 2025-10-22T04:20Z XXX followers, XX engagements


"@squawksquare Invest in $ALT and stop stressing with $TSLA"  
[X Link](https://x.com/PGainz96934/status/1981150271318478896) [@PGainz96934](/creator/x/PGainz96934) 2025-10-23T00:06Z XXX followers, XXX engagements


"🚨 Tomorrow we go deep. Ill be breaking down $ALT Pemvidutide vs $NVO Semaglutide the only other incretin ever approved for MASH. Were talking efficacy tolerability fibrosis data metabolic reach and why Pemvi is quietly setting up to be the Breakthrough Therapy candidate. Spoiler: its not even close. 💥 Retails been early before and well be early again. See you tomorrow for the full breakdown. #ALT #Pemvidutide #MASH #Biotech #RetailStrong"  
[X Link](https://x.com/PGainz96934/status/1981185695919087750) [@PGainz96934](/creator/x/PGainz96934) 2025-10-23T02:27Z XXX followers, XXX engagements


"@OddStockTrader 100%. Theyre still having PTSD flashbacks from 2021. Theyll throttle the buy button before they let retail run it back. But heres the thing every cycle has its own $GME moment it just wears a different ticker 😉"  
[X Link](https://x.com/PGainz96934/status/1981187163774734600) [@PGainz96934](/creator/x/PGainz96934) 2025-10-23T02:33Z XXX followers, XXX engagements